A. Sidney Barritt IV, MD, MSCR

Articles by A. Sidney Barritt IV, MD, MSCR

Future Advancements in PBC Care: Innovations on the Horizon

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

March 2nd 2026

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.

New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 23rd 2026

New studies reveal potential benefits of alfagimor in reducing fatigue and pruritus, highlighting its role in second-line therapy for patients.

Addressing Fatigue: Traditional Management Outside Primary Therapy

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 23rd 2026

In this episode, experts delve into the limited treatment options to address the symptom of fatigue in patients with primary biliary cholangitis. They highlight how small changes, like regular sleep schedules and exercise, can improve fatigue.

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 16th 2026

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 16th 2026

Explore the latest FDA-approved second-line therapies for PBC, including seladelpar and elafibranor, and their mechanisms of action.

How Special Populations and Disease Risk Impact Treatment Assessment in PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 9th 2026

Healthcare professionals discuss individualized approaches to second-line therapy for liver disease, considering patient age, fibrosis, and insurance challenges.

Experts Review the First- and Second-Line Treatment Options for PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 9th 2026

Experts discuss first-line treatments for Primary Biliary Cholangitis, emphasizing the importance of monitoring and patient compliance for effective management.

Diagnostic Criteria in PBC: What Clinicians are Looking For

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 2nd 2026

Learn how to diagnose Primary Biliary Cholangitis (PBC) through key criteria and the importance of specific autoantibodies in patient evaluation.

Assessing Disease Severity and Progression Risk in PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 2nd 2026

Explore the complexities of Primary Biliary Cholangitis (PBC), including risk factors, disease progression, and essential comorbidities for effective management.

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

January 26th 2026

Explore the complex relationship between pruritus, fatigue, and bone health in patients with primary biliary cholangitis (PBC).

An Overview of PBC Pathophysiology, Severity, and Burden

ByAparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD,Frances Lee, MD

January 26th 2026

Explore expert insights on primary biliary cholangitis, focusing on symptoms, treatment innovations, and emerging clinical data for effective patient management.